Flerie AB (publ)

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.

Flerie AB (publ) trades as FLERIE.ST on STO. The company is classified in Healthcare / Drug Manufacturers - General and reports in SEK.

The current profile places the business in Drug Manufacturers - General. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Flerie AB (publ) can be compared against peers such as BioInvent International AB (publ), Diamyd Medical AB (publ), Devyser Diagnostics AB (publ), Egetis Therapeutics AB (publ), Hansa Biopharma AB (publ), Humana AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.92B, beta of -0.13, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FLERIE.ST currently shows total debt of N/A and beta of -0.13. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.flerie.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.